Evidence map›Paper›PMID 25223604›Full record

SynthesisJournal of Crohn's & colitis2014

Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis.

Ruben J Colman, David T Rubin

RetractedErratum issued 5 registry-linked trialsAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of Crohn's & colitis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. It is linked to 5 registered trials, which are not on this map. Cited by 236 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
236citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02952131 phase1 / phase2suspendednot on this mapstarted 2016, after this paper: background citation

Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease

TypeinterventionalSponsorHealeon Medical IncRan2016 to 2026Enrolled100ConditionsInflammatory Bowel DiseasesArmsLipoaspiration, AD-cSVF, Normal Saline IV
NCT03279224 phase2 / phase3unknown statusnot on this mapstarted 2018, after this paper: background citation

A Randomized Controlled Trial of the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder

TypeinterventionalSponsorValerie TaylorRan2018 to 2022Enrolled35ConditionsBipolar DepressionArmsAllogenic FMT, Autologous FMT
NCT03483246 phase3active not recruitingnot on this mapstarted 2018, after this paper: background citation

Impact of Fecal Microbiota Transplantation in Ulcerative Colitis: a Randomized, Sham Controlled Trial

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2018 to 2027Enrolled150ConditionsUlcerative ColitisArmsFecal Microbiota Transplantation (FMT), Sham-transplantation Placebo
NCT04997733 phase3recruitingnot on this mapstarted 2021, after this paper: background citation

Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2021 to 2029Enrolled150ConditionsCrohn DiseaseArmsFecal Microbiota Transplantation (FMT), Sham-transplantation (placebo)
NCT05174273 phase2 / phase3active not recruitingnot on this mapstarted 2022, after this paper: background citation

Understanding the Neurocognitive Effects of Fecal Microbiota Transplantation in Major Depressive Disorder Patients With and Without Irritable Bowel Syndrome

TypeinterventionalSponsorValerie TaylorRan2022 to 2026Enrolled133ConditionsMajor Depressive Disorder, Irritable Bowel SyndromeArmsFecal Microbiota Transplantation
3 · Its place in the literature

Who cites it

236 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Fecal transplantation for treatment of inflammatory bowel disease.The Cochrane database of systematic reviews · 2018
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

176 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Ruben J ColmanInflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, IL, USA. Electronic address: rcolman@medicine.bsd.uchicago.edu.
David T RubinInflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, IL, USA. Electronic address: drubin@medicine.bsd.uchicago.edu.

Funding

ULTRASTRUCTURE AND CYTOMORPHOLOGY COREP30DK042086 · NIDDK · UNIVERSITY OF CHICAGO · PI CHANG, EUGENE B · 1990 to 2025
$29.8M
Re-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2M
NCATS NIH HHS UL1 TR000430NIDDK NIH HHS P30 DK042086NIDDK NIH HHS P30DK42086
6 · The paper itself

Abstract

BACKGROUND AND

aimsFecal microbiota transplantation (FMT) has gained interest as a novel treatment option for inflammatory bowel diseases (IBD). While publications describing FMT as therapy for IBD have more than doubled since 2012, research that investigates FMT treatment efficacy has been scarce. We conducted a systematic review and meta-analysis to evaluate the efficacy of FMT as treatment for patients with IBD.

methodsA systematic literature search was performed through May 2014. Inclusion criteria required FMT as the primary therapeutic agent. Clinical remission (CR) and/or mucosal healing were defined as primary outcomes. Studies were excluded if they did not report clinical outcomes or included patients with infections.

resultsEighteen studies (9 cohort studies, 8 case studies and 1 randomized controlled trial) were included. 122 patients were described (79 ulcerative colitis (UC); 39 Crohn's disease (CD); 4 IBD unclassified). Overall, 45% (54/119) of patients achieved CR during follow-up. Among the cohort studies, the pooled proportion of patients that achieved CR was 36.2% (95% CI 17.4%-60.4%), with a moderate risk of heterogeneity (Cochran's Q, P=0.011; I(2)=37%). Subgroup analyses demonstrated a pooled estimate of clinical remission of 22% (95% CI 10.4%-40.8%) for UC (P=0.37; I(2)=0%) and 60.5% (95% CI 28.4%-85.6%) for CD (P=0.05; I(2)=37%). Six studies performed microbiota analysis.

conclusionsThis analysis suggests that FMT is a safe, but variably efficacious treatment for IBD. More randomized controlled trials are needed and should investigate frequency of FMT administration, donor selection and standardization of microbiome analysis.

Indexed as

FecesGastrointestinal TractHumansInflammatory Bowel DiseasesIntestinal MucosaMicrobiotaRemission InductionTransplantationFecal microbiota transplantationInflammatory bowel diseaseMeta-analysisMicrobiomeMucosal healingSystematic review

Identifiers

PMID25223604
PMCPMC4296742

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.